Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.

Lopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A, Zammataro L, Manzano A, Manara P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Raspagliesi F, Angioli R, Buza N, Hui P, Bond HM, Santin AD.

Oncotarget. 2020 Feb 4;11(5):560-570. doi: 10.18632/oncotarget.27342. eCollection 2020 Feb 4.

2.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.

Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin A.

Sci Rep. 2020 Jan 22;10(1):973. doi: 10.1038/s41598-020-58009-3.

3.

The Missing "lnc" between Genetics and Cardiac Disease.

Azodi M, Kamps R, Heymans S, Robinson EL.

Noncoding RNA. 2020 Jan 14;6(1). pii: E3. doi: 10.3390/ncrna6010003.

4.

Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.

Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD.

Mol Oncol. 2019 Dec 31. doi: 10.1002/1878-0261.12627. [Epub ahead of print]

5.

In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.

Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD.

Gynecol Oncol. 2020 Feb;156(2):430-438. doi: 10.1016/j.ygyno.2019.11.018. Epub 2019 Dec 12.

PMID:
31839338
6.

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.

Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD.

Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22730-22736. doi: 10.1073/pnas.1911385116. Epub 2019 Oct 17.

PMID:
31624127
7.

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.

Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD.

Gynecol Oncol. 2019 Oct;155(1):144-150. doi: 10.1016/j.ygyno.2019.08.010. Epub 2019 Aug 18.

PMID:
31434613
8.

Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer.

Seifi F, Parkash V, Clark M, Menderes G, Tierney C, Silasi DA, Azodi M.

JSLS. 2019 Apr-Jun;23(2). pii: e2019.00021. doi: 10.4293/JSLS.2019.00021.

9.

Uterine Artery-sparing Minimally Invasive Radical Trachelectomy: A Case Report and Review of the Literature.

Kim S, Chung S, Azodi M, Menderes G.

J Minim Invasive Gynecol. 2019 Nov - Dec;26(7):1389-1395. doi: 10.1016/j.jmig.2019.05.017. Epub 2019 Jun 4.

PMID:
31173940
10.

A Novel Approach to Combined Vaginal and Laparoscopic Gynecological Surgery.

Tierney C, Chung SH, Feinberg J, Haines K, Yadav G, Azodi M, Menderes G.

JSLS. 2019 Apr-Jun;23(2). pii: eJSLS.2019.00006. doi: 10.4293/JSLS.2019.00006.

11.

Robotic Surgery: Research and Reviews is indexed in PubMed.

Azodi M, Hesson D.

Robot Surg. 2019 Mar 26;6:1-2. doi: 10.2147/RSRR.S204381. eCollection 2019. No abstract available.

12.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.

Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

PMID:
30948273
13.

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2019 Apr;153(1):158-164. doi: 10.1016/j.ygyno.2019.01.002. Epub 2019 Jan 7.

PMID:
30630630
14.

Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes.

Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE.

Gynecol Obstet Invest. 2019;84(3):290-297. doi: 10.1159/000493132. Epub 2019 Jan 2.

15.

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.

Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):619-624. doi: 10.1073/pnas.1814027116. Epub 2018 Dec 24. Erratum in: Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5829.

16.

Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.

Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES.

J Cancer Res Clin Oncol. 2018 Dec;144(12):2449-2456. doi: 10.1007/s00432-018-2753-y. Epub 2018 Sep 25.

PMID:
30255380
17.

Introducing Transthyretin as a Differentially Expressed Protein in Washing Subtype of Obsessive-Compulsive Disorder.

Azodi MZ, Tavirani MR, Oskouie AA, Mansouri V, Hamdieh M, Nejati N, Hamid-Pour M, Ahmadzadeh A, Rostami-Nejat M, Tavirani MR, Tabatabaei SAM.

Basic Clin Neurosci. 2018 May-Jun;9(3):187-194. doi: 10.29252/NIRP.BCN.9.3.187.

18.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.

Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD.

Clin Cancer Res. 2018 Oct 1;24(19):4845-4853. doi: 10.1158/1078-0432.CCR-18-0864. Epub 2018 Jun 25.

19.

Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.

Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE.

Reprod Sci. 2019 May;26(5):600-608. doi: 10.1177/1933719118778801. Epub 2018 May 29.

PMID:
29843577
20.

Laparoscopic Ligation of Uterine Vasculature for Fertility-Sparing Management of Postabortal Hemorrhage.

Menderes G, Leon-Martinez D, Azodi M.

J Minim Invasive Gynecol. 2019 Jan;26(1):36-37. doi: 10.1016/j.jmig.2018.03.020. Epub 2018 Mar 30.

PMID:
29609031
21.

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD.

J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27.

PMID:
29584549
22.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2018 Jun;149(3):585-591. doi: 10.1016/j.ygyno.2018.03.050. Epub 2018 Mar 21.

23.

In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.

Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Mol Cancer Ther. 2018 May;17(5):1003-1011. doi: 10.1158/1535-7163.MCT-17-0930. Epub 2018 Feb 13.

24.

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer.

Albright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE.

Gynecol Oncol Rep. 2018 Jan 9;23:28-33. doi: 10.1016/j.gore.2018.01.003. eCollection 2018 Feb.

25.

Amendment of Agricultural Soil with Metal Nanoparticles: Effects on Soil Enzyme Activity and Microbial Community Composition.

Asadishad B, Chahal S, Akbari A, Cianciarelli V, Azodi M, Ghoshal S, Tufenkji N.

Environ Sci Technol. 2018 Feb 20;52(4):1908-1918. doi: 10.1021/acs.est.7b05389. Epub 2018 Feb 8.

PMID:
29356510
26.

Minimally invasive abdominal cerclage compared to laparotomy: a comparison of surgical and obstetric outcomes.

Kim S, Hill A, Menderes G, Cross S, Azodi M, Bahtiyar MO.

J Robot Surg. 2018 Jun;12(2):295-301. doi: 10.1007/s11701-017-0726-9. Epub 2017 Jul 18.

PMID:
28721634
27.

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.

Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Oct;147(1):145-152. doi: 10.1016/j.ygyno.2017.07.009. Epub 2017 Jul 10.

28.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Clin Cancer Res. 2017 Oct 1;23(19):5836-5845. doi: 10.1158/1078-0432.CCR-16-2862. Epub 2017 Jul 5.

29.

Natural Orifice-Assisted Laparoscopic Meckel Diverticulectomy Incidentally Found During Para-Aortic Mass Resection.

Menderes G, Dugan K, Klein MJ, Azodi M.

J Minim Invasive Gynecol. 2018 Jan;25(1):19-20. doi: 10.1016/j.jmig.2017.04.015. Epub 2017 May 3.

PMID:
28478192
30.

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.

Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Jul;146(1):179-186. doi: 10.1016/j.ygyno.2017.04.023. Epub 2017 May 1.

31.

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.

Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Med Oncol. 2017 May;34(5):91. doi: 10.1007/s12032-017-0956-8. Epub 2017 Apr 10.

32.

Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma.

Deshmukh U, McAdow M, Black J, Hui P, Azodi M.

Gynecol Oncol Rep. 2017 Mar 6;20:54-57. doi: 10.1016/j.gore.2017.03.001. eCollection 2017 May.

33.

Dissolution Behavior of Silver Nanoparticles and Formation of Secondary Silver Nanoparticles in Municipal Wastewater by Single-Particle ICP-MS.

Azodi M, Sultan Y, Ghoshal S.

Environ Sci Technol. 2016 Dec 20;50(24):13318-13327. Epub 2016 Dec 6.

PMID:
27993044
34.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.

Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD.

Mol Cancer Ther. 2017 Feb;16(2):323-333. doi: 10.1158/1535-7163.MCT-16-0501. Epub 2016 Dec 12.

35.

Robot-Assisted Abdominal Cerclage During Pregnancy.

Zeybek B, Hill A, Menderes G, Borahay MA, Azodi M, Kilic GS.

JSLS. 2016 Oct-Dec;20(4). pii: e2016.00072.

36.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Jan;144(1):146-152. doi: 10.1016/j.ygyno.2016.11.023. Epub 2016 Nov 26.

37.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10.

38.

Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.

Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES.

Gynecol Oncol. 2017 Jan;144(1):77-82. doi: 10.1016/j.ygyno.2016.09.027. Epub 2016 Oct 24.

PMID:
27789084
39.

Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer.

Gojayev A, English DP, Macer M, Azodi M.

Case Rep Obstet Gynecol. 2016;2016:8547173. Epub 2016 Sep 25.

40.

The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy.

Hill AM, Davis KM, Clark-Donat L, Hammons LM, Azodi M, Silasi DA.

J Minim Invasive Gynecol. 2017 Jan 1;24(1):108-113. doi: 10.1016/j.jmig.2016.09.015. Epub 2016 Oct 1.

PMID:
27702701
41.

The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy.

Tower AM, Clark Donat L, Azodi M, Silasi DA.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S77. doi: 10.1016/j.jmig.2015.08.205. Epub 2015 Oct 15. No abstract available.

PMID:
27679335
42.

Identifying Risk Factors for Urinar y Retention After Hysterectomy for Leiomyoma.

Clark Donat L, Tower A, Clark M, Silasi DA, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S59. doi: 10.1016/j.jmig.2015.08.157. Epub 2015 Oct 15. No abstract available.

PMID:
27679285
43.

Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival?

Clark M, Glasgow M, Menderes G, Azodi M, Silasi DA.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S48-S49. doi: 10.1016/j.jmig.2015.08.134. Epub 2015 Oct 15. No abstract available.

PMID:
27679256
44.

Comparison of Robotics Versus Conventional Laparoscopy for Management of Benign Adnexal Masses.

Zigras T, Goodman L, Menderes G, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S22-S23. doi: 10.1016/j.jmig.2015.08.069. Epub 2015 Oct 15. No abstract available.

PMID:
27679091
45.

Laparoscopic Ovarian Transposition.

Kakar F, English D, Menderes G, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S153. doi: 10.1016/j.jmig.2015.08.566. Epub 2015 Oct 15. No abstract available.

PMID:
27678870
46.

Techniques for Removing Pelvic Masses.

Clark Donat L, Tower AM, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S146. doi: 10.1016/j.jmig.2015.08.520. Epub 2015 Oct 15. No abstract available.

PMID:
27678815
47.

Pararectal Space Dissection for Treatment of Endometriosis.

Tower AM, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S138. doi: 10.1016/j.jmig.2015.08.461. Epub 2015 Oct 15. No abstract available.

PMID:
27678755
48.

Combined Natural Orifice Single-Site Hysterectomy.

Tower AM, Schwab C, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S127. doi: 10.1016/j.jmig.2015.08.389. Epub 2015 Oct 15. No abstract available.

PMID:
27678681
49.

An Extra Step to Prevent Troublesome Uterine Artery Bleeding: Retroperitoneal Dissection and Ligation of the Uterine Artery at the Source.

Tower AM, Azodi M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S127. doi: 10.1016/j.jmig.2015.08.391. Epub 2015 Oct 15. No abstract available.

PMID:
27678679
50.

The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer.

Menderes G, Black JD, Azodi M.

Expert Rev Anticancer Ther. 2016 Sep;16(9):899-901. doi: 10.1080/14737140.2016.1219658. Epub 2016 Aug 9. No abstract available.

PMID:
27477495

Supplemental Content

Support Center